Biopiezoelectric-based nanomaterials; a promising strategy in cancer therapy.

IF 11.4 1区 医学 Q1 ONCOLOGY
Tingting Zuo, Saikat Dewanjee, Chao Zhang, Pratik Chakraborty, Wanxia Lu, Niraj Kumar Jha, Hiranmoy Bhattacharya, Moumita Gangopadhyay, Joshua Fleishman, Saurabh Kumar Jha, Zhe-Sheng Chen
{"title":"Biopiezoelectric-based nanomaterials; a promising strategy in cancer therapy.","authors":"Tingting Zuo, Saikat Dewanjee, Chao Zhang, Pratik Chakraborty, Wanxia Lu, Niraj Kumar Jha, Hiranmoy Bhattacharya, Moumita Gangopadhyay, Joshua Fleishman, Saurabh Kumar Jha, Zhe-Sheng Chen","doi":"10.1186/s13046-025-03427-2","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer is one of the deadliest diseases, continually prompting physicians and researchers to investigate safe and effective modalities for its treatment. Piezoelectric nanomaterial is a new class of material with enormous potential for the nanoscale and bidirectional conversion of mechanical strain into electric fields for cancer treatment. In response to ultrasound mechanical strain, a piezopotential and electric field is generated in the tumor microenvironment, which reduces the growth of cancer cells by catalyzing redox reactions and the synthesis of reactive oxygen species. In this review, we discuss the basic concepts and mechanisms of biopiezoelectric nanomaterials as anti-cancer agents. We provide a comprehensive summary of current state-of-the-art piezoelectric nanoparticles as anti-cancer therapies. Lastly, we identify current challenges that must be addressed for the proper clinical development of biopiezoelectric nanomaterial-based anti-cancer agents and provide future perspectives for the development of this technology.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"44 1","pages":"171"},"PeriodicalIF":11.4000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental & Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13046-025-03427-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer is one of the deadliest diseases, continually prompting physicians and researchers to investigate safe and effective modalities for its treatment. Piezoelectric nanomaterial is a new class of material with enormous potential for the nanoscale and bidirectional conversion of mechanical strain into electric fields for cancer treatment. In response to ultrasound mechanical strain, a piezopotential and electric field is generated in the tumor microenvironment, which reduces the growth of cancer cells by catalyzing redox reactions and the synthesis of reactive oxygen species. In this review, we discuss the basic concepts and mechanisms of biopiezoelectric nanomaterials as anti-cancer agents. We provide a comprehensive summary of current state-of-the-art piezoelectric nanoparticles as anti-cancer therapies. Lastly, we identify current challenges that must be addressed for the proper clinical development of biopiezoelectric nanomaterial-based anti-cancer agents and provide future perspectives for the development of this technology.

Biopiezoelectric-based纳米材料;一个很有前途的癌症治疗策略。
癌症是最致命的疾病之一,不断促使医生和研究人员研究安全有效的治疗方法。压电纳米材料是一种新型材料,具有巨大的纳米级和双向机械应变转化为电场治疗癌症的潜力。在超声机械应变的作用下,肿瘤微环境中产生一个压电场和电场,通过催化氧化还原反应和活性氧的合成来降低癌细胞的生长。本文综述了生物压电纳米材料作为抗癌剂的基本概念和作用机制。我们提供了一个全面的总结,目前最先进的压电纳米粒子作为抗癌疗法。最后,我们确定了当前基于生物压电纳米材料的抗癌药物的临床开发必须解决的挑战,并为该技术的发展提供了未来的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
18.20
自引率
1.80%
发文量
333
审稿时长
1 months
期刊介绍: The Journal of Experimental & Clinical Cancer Research is an esteemed peer-reviewed publication that focuses on cancer research, encompassing everything from fundamental discoveries to practical applications. We welcome submissions that showcase groundbreaking advancements in the field of cancer research, especially those that bridge the gap between laboratory findings and clinical implementation. Our goal is to foster a deeper understanding of cancer, improve prevention and detection strategies, facilitate accurate diagnosis, and enhance treatment options. We are particularly interested in manuscripts that shed light on the mechanisms behind the development and progression of cancer, including metastasis. Additionally, we encourage submissions that explore molecular alterations or biomarkers that can help predict the efficacy of different treatments or identify drug resistance. Translational research related to targeted therapies, personalized medicine, tumor immunotherapy, and innovative approaches applicable to clinical investigations are also of great interest to us. We provide a platform for the dissemination of large-scale molecular characterizations of human tumors and encourage researchers to share their insights, discoveries, and methodologies with the wider scientific community. By publishing high-quality research articles, reviews, and commentaries, the Journal of Experimental & Clinical Cancer Research strives to contribute to the continuous improvement of cancer care and make a meaningful impact on patients' lives.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信